Key Highlights
- Shares of TNGX rallied 45% following disclosure of a 92% objective response rate in pancreatic cancer patients treated with vopimetostat combined with daraxonrasib
- The drug combination delivered 100% disease control across 12 evaluable patients, with 90% remaining progression-free at the 6-month milestone
- An alternative pairing — vopimetostat with zoldonrasib — demonstrated a 52% objective response rate among 27 patients
- Safety profiles remained favorable for both combinations; zero Grade 4 or 5 adverse reactions, zero discontinuations due to side effects
- The biotech plans Phase 3 initiation for the vopimetostat/daraxonrasib combination targeting first-line MTAP-deleted pancreatic cancer during the second half of 2026
Shares of Tango Therapeutics (TNGX) surged 45% during Monday’s premarket session following the biotech’s announcement of encouraging early-stage clinical results demonstrating its experimental drug pairing reduced tumor burden in virtually all participants with late-stage pancreatic cancer.
Tango Therapeutics, Inc., TNGX
The standout figure: a 92% objective response rate among participants receiving vopimetostat alongside Revolution Medicines’ daraxonrasib. This translates to 11 out of 12 evaluable individuals with metastatic pancreatic ductal adenocarcinoma showing positive treatment response.
The drug pairing further achieved complete disease control across all patients. Among these responses, nine of the 11 received confirmation, while 90% of trial participants remained free of disease progression through the 6-month evaluation point.
The study population consisted of individuals with second- and third-line metastatic disease — patients who had exhausted previous therapeutic options. More than 70% presented with liver metastases.
Median progression-free survival remained unreached at the May 28 data snapshot, typically considered an encouraging indicator during this phase of clinical development.
Trial participants received either 200mg or 250mg of vopimetostat daily, paired with 100mg daily doses of daraxonrasib. The dataset encompasses 59 total participants spanning both pancreatic cancer and non-small cell lung cancer cohorts.
Additional Combination Demonstrates Encouraging Activity
The company simultaneously unveiled outcomes from an alternate drug pairing — vopimetostat combined with Revolution’s zoldonrasib — tested in 27 evaluable pancreatic cancer participants.
This cohort produced a 52% objective response rate alongside a 74% progression-free survival rate at 6 months. Tumor reduction occurred in 14 of the 27 enrolled patients.
While less dramatic compared to the daraxonrasib cohort, these findings reinforce vopimetostat’s therapeutic promise when paired with various partner agents.
Safety data proved encouraging across both treatment arms. The majority of adverse reactions fell into Grade 1 or 2 categories. For the daraxonrasib combination, rash, stomatitis/mucositis, and diarrhea represented the most frequently observed side effects. Neither Grade 4 nor Grade 5 events occurred, and treatment-related discontinuations were absent.
Future Development Plans
The biotech intends to progress the vopimetostat and daraxonrasib combination into Phase 3 clinical testing. The intended population: treatment-naive patients with MTAP-deleted pancreatic cancer.
Tango anticipates finalizing Phase 3 protocol design during the latter half of 2026, subject to regulatory agency consultations.
MTAP deletions appear in approximately 40% of pancreatic malignancies and roughly 15% of lung cancers — representing a well-defined patient subset that provides precise genetic enrollment criteria for the trial.
These results emerge merely one week following Revolution Medicines’ presentation of daraxonrasib data at ASCO, where the compound demonstrated doubled survival outcomes in pancreatic cancer cohorts.
Tango’s vopimetostat represents an orally administered therapeutic specifically engineered to target malignant cells harboring MTAP deletions.
Revolution Medicines (RVMD) stock declined 4.15% during the trading session.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
